In Indiana, Scientists Discover 'Fountain Of Youth' Gene In Isolated Amish Community

Researchers from the Indiana Hemophilia & Thrombosis Center (IHTC) and Northwestern University say a genetic mutation in some Old Order Amish living in Indiana protects them from effects of aging.

Their research shows a population of at least 70 genetically-isolated Amish individuals from Berne, Indiana live on average 10 years longer than their peers and families. The longer lifespan is thanks to a single-gene mutation which causes them to have very low levels of a protein called plasminogen activator inhibitor-1, also called PAI-1.

Dr. Amy Shapiro, the founder and CEO of the Indiana Hemophilia & Thrombosis Center, says this discovery has been a long time coming.

In 1990, Shapiro heard about a young Amish girl who was experiencing severe bleeding after bumping her head as a toddler. The girl’s condition had gone undiagnosed for seven years, and Shapiro took interest.

“I thought because she was from the Amish that it was likely that she had some rare recessive disorder,” she says.

Because the Amish often marry within their existing families, Shapiro says certain recessive disorders are common.

Shapiro decided to test the girl for PAI-1 deficiency and found it was the cause of the severe bleeding.

For the girl to have been born with PAI-1 deficiency, both of her parents had to have a single copy of the mutated gene. Both parents passed down each of their single mutated genes, resulting in the girl receiving two mutated genes instead of just one.

Shapiro, in conjunction with genetic counselors at IHTC, set out to find the origin of the gene and to determine which Amish families were at risk of passing the gene on to their children.

“So, over the course of the last 27 years, we have found 12 people in the community with this bleeding disorder,” she says.

Shapiro says her team then wondered if carriers of the condition — people with only one copy of the gene – might actually benefit from their low, but not absent levels of PAI-1.

“And we wondered, well, since they might have lowered PAI-1, maybe their risk of cardiovascular disease was better than the normal population,” she says.

The scientists also found people with the mutation had a less diabetes and lower levels of insulin as well as more flexible blood vessels.

Shapiro worked with the chair of the Northwestern University Department of Medicine to conduct a large study of 177 Amish in Berne in 2015.

Scientists working with Northwestern found that Amish with two copies of the gene not only had an excessive bleeding disorder, but also presented with symptoms of cardiac fibrosis.

Shapiro says their 27-year research process isn’t over yet. She says she hopes to conduct more research with help of the Amish to study how PAI-1 relates to cognitive function, exercise and other factors.

Before you buy a computer, or a used car or even a pair of pants, you probably know the price you'll pay. The same is not always true when buying health care. But as people pay and more of their health care costs—thanks in part to high-deductible health plans—there's growing demand to know prices upfront. It's a concept known as price transparency.

One hospital in rural Missouri is catering to that demand, by developing a price-list for medical procedures. For help, the hospital is turning to a group who've been getting price transparency for years: the Amish and Mennonites.

Research at Johns Hopkins has helped a team of scientists elsewhere identify and develop a compound that could directly target a genetic mutation responsible for a common familial form of amyotrophic lateral sclerosis (ALS) and a biologically related memory-robbing disease known as frontotemporal dementia (FTD).

Content on this site provides general information relating to health and is not intended to be a substitute for consultation